Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support for eligible patients with amyotrophic lateral sclerosis (ALS) treated with RADICAVA® (edaravone) through more efficient communication and exchange of information, including a new “hybrid” card that can be used to help access appropriate pharmacy and medical co-pay assistance.
JERSEY CITY, N.J., Jan. 14, 2021 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced upgrades to its out-of-pocket assistance program that aim to provide enhanced support for eligible patients with amyotrophic lateral sclerosis (ALS) treated with RADICAVA® (edaravone) through more efficient communication and exchange of information, including a new “hybrid” card that can be used to help access appropriate pharmacy and medical co-pay assistance. “Our modified ‘all-in-one’ out-of-pocket assistance program was designed with our patients in mind, to continue to support appropriate, affordable access to treatment with RADICAVA, for eligible patients,” said Kevin O’Brien, Vice President of Market Access, MTPA. “We changed the program processes for handling pharmacy and medical benefit claims to allow patients to use one card, on-the-spot. In addition, we have modified logistical procedures related to co-pay issues for healthcare providers.” Through the Searchlight Support® Out-of-Pocket Assistance Program, eligible patients with commercial insurance may be able to pay as little as $0 per infusion by having applicable out-of-pocket costs for deductibles, co-pay and co-insurance for medication and covered up to $20,000 per calendar year.* For additional information, visit Searchlight Support online or call 1-844-772-4548. *Assistance is not valid for patients covered, in whole or in part, by government health insurance (i.e., Medicare, Medicaid, Veterans Administration, Department of Defense, or other federal or state assistance programs), and other restrictions may apply. Patients residing in Massachusetts, Minnesota, Michigan and Rhode Island are eligible for assistance for the cost of the drug only and are not eligible for cost support for administration of the medication. Patients may be responsible for any costs associated with RADICAVA and infusion above the maximum annual program benefit. About RADICAVA® (edaravone) IV IMPORTANT SAFETY INFORMATION
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of RADICAVA?
The most common side effects of RADICAVA include bruising (contusion), problems walking (gait disturbance), and headache. These are not all the possible side effects of RADICAVA. Call your healthcare provider for medical advice about side effects. You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For more information, including full Prescribing Information and Patient Information, please visit www.RADICAVA.com. About Mitsubishi Tanabe Pharma America, Inc. Overview of Mitsubishi Tanabe Pharma Corporation Media inquiries: _______________________________ 1 RADICAVA® U.S. Prescribing Information. August 2018.
SOURCE Mitsubishi Tanabe Pharma America, Inc. |